Panobinostat (Farydak)
Other Medications · Approved since 2015
Description
Panobinostat is a pan-histone deacetylase (HDAC) inhibitor that has been explored in combination therapy regimens for metastatic colorectal cancer. This epigenetic modifier is FDA-approved for multiple myeloma but has been studied off-label in colorectal cancer, particularly in combination with fluorouracil-based chemotherapy and immunotherapy agents. The drug works to restore normal gene expression patterns that are disrupted in cancer cells through chromatin remodeling.
Mechanism of Action
Panobinostat inhibits multiple classes of histone deacetylase enzymes (Class I, II, and IV HDACs), leading to increased acetylation of histone and non-histone proteins. This epigenetic modification results in chromatin relaxation, reactivation of tumor suppressor genes, cell cycle arrest, and enhanced apoptosis in cancer cells. The HDAC inhibition also enhances the antitumor activity of other therapeutic agents by increasing DNA damage and improving immune recognition of tumor cells.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Farydak |
| Category | Other Medications |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | Oral |
| Year Approved | 2015 |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.